晚期前列腺癌治疗心脏毒性图谱(PROXMAP):基于贝叶斯模型治疗史的系统评价与网络Meta分析
本研究通过系统评价与网络Meta分析(13项RCT,16292例患者),评估mHSPC、M0CRPC和mCRPC一线治疗的心脏毒性。在mHSPC中,ADT+DTX+AA+P较ADT+DTX显著增加高血压和心律失常风险,而ADT+DTX+DAR无此差异;在mCRPC中,ADT+AA+P+OLA较ADT+AA+P显著降低高血压风险。M0CRPC结果无显著差异。
要点
- mHSPC中ADT+DTX+AA+P较ADT+DTX显著增加高血压(RR 2.85)和心律失常(RR 2.01)风险。
- mHSPC中ADT+DTX+DAR与ADT+DTX相比高血压(RR 1.55)和心律失常(RR 0.94)无显著差异。
- mCRPC中ADT+AA+P+OLA较ADT+AA+P显著降低高血压风险(RR 0.20)。
核心结论
- 对于mHSPC,ADT+DTX+DAR较ADT+DTX+AA+P心脏毒性更少,因盐皮质激素过剩减少而降低高血压和心律失常风险。
- 对于mCRPC,在mHSPC治疗后雄激素剥夺基础上,ADT+AA+P联合OLA较ADT+AA+P反常地降低高血压风险。
研究设计与样本
- 系统评价与网络Meta分析,检索Ovid Medline、Elsevier Embase和Cochrane Library从建库至2024年1月14日的随机对照试验。
- 纳入13项RCT,共16292例患者,针对mHSPC、M0CRPC和mCRPC一线治疗构建网络Meta分析。
- 采用贝叶斯网络Meta分析并考虑既往治疗史。
主要发现
- mHSPC中,ADT+DTX+AA+P较ADT+DTX显著增加高血压(RR 2.85,95%CI 1.67-4.89)和心律失常(RR 2.01,95%CI 1.17-3.44)。
- mHSPC中,ADT+DTX+DAR与ADT+DTX相比高血压(RR 1.55,95%CI 0.73-3.30)和心律失常(RR 0.94,95%CI 0.63-1.40)无显著差异。
- mCRPC假设有mHSPC治疗史时,ADT+AA+P+OLA较ADT+AA+P显著降低高血压(RR 0.20,95%CI 0.16-0.26)。
- M0CRPC结果无显著差异。
关键数值与推荐
- 心脏毒性指标依据国际心脏肿瘤学会定义:心力衰竭、心肌炎、血管毒性、高血压和心律失常。
- mHSPC中ADT+DTX+AA+P较ADT+DTX高血压RR 2.85(95%CI 1.67-4.89),心律失常RR 2.01(95%CI 1.17-3.44)。
- mHSPC中ADT+DTX+DAR较ADT+DTX高血压RR 1.55(95%CI 0.73-3.30),心律失常RR 0.94(95%CI 0.63-1.40)。
- mCRPC中ADT+AA+P+OLA较ADT+AA+P高血压RR 0.20(95%CI 0.16-0.26)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Recommendations of first-line therapies for metastatic hormone-sensitive (mHSPC), nonmetastatic castrate-resistant (M0CRPC), and metastatic castrate-resistant (mCRPC) prostate cancer do not account for cardiotoxicity due to a lack of clear prior evidence. This manuscript assesses cardiotoxicity of these therapies. METHODS: We searched Ovid Medline, Elsevier Embase, and the Cochrane Library for randomized clinical trials (RCTs) from database inception to January 14, 2024. Network meta-analyses of first-line mHSPC, M0CRPC, and mCRPC therapies were constructed for the five cardiotoxicity metrics defined by the International Cardio-Oncology Society: heart failure, myocarditis, vascular toxicity, hypertension, and arrhythmias. Additional Bayesian network meta-analyses also accounted for prior treatment history. KEY FINDINGS AND LIMITATIONS: Thirteen RCTs (16 292 patients) were included. For mHSPC, androgen deprivation therapy (ADT) plus docetaxel (DTX) plus abiraterone acetate (AA) with prednisone (P) demonstrated a significant increase in hypertension and arrhythmias versus ADT + DTX (risk ratio [RR] 2.85, 95% confidence interval [CI] 1.67-4.89, and RR 2.01, 95% CI 1.17-3.44, respectively); however, no corresponding differences were observed between ADT + DTX plus darolutamide (DAR) and ADT + DTX (RR 1.55, 95% CI 0.73-3.30, and RR 0.94, 95% CI 0.63-1.40, respectively). For mCRPC assuming a history of mHSPC treatment, ADT + AA + P plus olaparib (OLA) demonstrated a statistically significant decrease in hypertension versus ADT + AA + P (RR 0.20, 95% CI 0.16-0.26). M0CRPC results were unremarkable. CONCLUSIONS AND CLINICAL IMPLICATIONS: For mHSPC, ADT + DTX + DAR demonstrates less cardiotoxicity than ADT + DTX + AA + P due to a lower risk of hypertension and arrhythmias from decreased mineralocorticoid excess. In addition, OLA counterintuitively offers decreased hypertension when superimposed on ADT + AA + P for mCRPC treatment after prior androgen deprivation from mHSPC therapy.
引用
- Aziz MK, Molony D, Monlezun D, et al. Prostate Cancer Therapy Cardiotoxicity Map (PROXMAP) for Advanced Disease States: A Systematic Review and Network Meta-analysis with Bayesian Modeling of Treatment Histories. Eur Urol. 2024. PMID: 39299896. doi:10.1016/j.eururo.2024.08.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。